Back to overview

Swiss HIV Cohort Study

English title Swiss HIV Cohort Study
Applicant Francioli Patrick Bernard
Number 108787
Funding scheme Cohort Studies Large
Research institution Service de Médecine Préventive Hospitalière CHUV
Institution of higher education University of Lausanne - LA
Main discipline Clinical Immunology and Immunopathology
Start/End 01.04.2006 - 31.12.2010
Approved amount 15'487'750.00
Show all

All Disciplines (2)

Clinical Immunology and Immunopathology
Infectious Diseases

Keywords (2)

AIDS; HIV Cohort

Lay Summary (English)

Lay summary
The Swiss HIV Cohort Study (SHCS) was established in 1988 with the help of the Swiss Federal Office of Public Health. Since several years, the study is funded by the Swiss National Science Foundation. It is an observational study of HIV-infected residents in Switzerland aged 16 years or older. The study is a collaboration of seven centers (the five Swiss university hospitals situated in Basel, Bern, Geneva, Lausanne and Zurich, and two reference hospitals in St.Gallen and Lugano). It is managed by the Co-ordination and Data center in Lausanne and is estimated to cover about 69% of people with AIDS living in Switzerland and 45% of the cumulated number of HIV infections declared to the Swiss health authorities.

The study serves also as a logistical network for research in the field of HIV. Objectives include epidemiological-, clinical-, laboratory- and health service research, as well as improving service and infrastructure for future projects. An important number of nested research projects are performed in this framework. These projects benefit of the infrastructure, collected data and stored blood samples and are financed by the funds allocated by the SNSF.

Data collection
A standardized protocol is used for data collection. A variety of data are recorded at entry to the study, i.e. year of birth, gender and presumed mode of transmission. Categories of presumed transmission include men having sex with men, heterosexually infected patients, injecting drug users, patients infected via blood products and patients with unknown route of infection. Laboratory and clinical data are obtained at each semi-annual follow-up visit. Additional interim CD3/4/8 and viral load determinations are recorded, if available. Some serological laboratory tests are carried out at registration. The antiretroviral treatment is documented in detail. Information that has become relevant in later years has been added to the study protocol (i.e. adverse events of antiretroviral drugs, adherence to drug therapy and cardiovascular risk factors). Data quality is regularly checked by the data center and a quality incentive system is in place in which centers with insufficient data quality are motivated with deductions from the financial support. The data collection is strictly anonymous and informed consent is obtained at registration.
Routine analyses are carried out regularly and include trends in transmission mode and gender, number of registrations and of patients under follow-up, type of health care provider as well as antiretroviral treatment

More information on internet:

Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants

Name Institute

Associated projects

Number Title Start Funding scheme
127631 Contribution of multiple genetic variants, identified in genome-wide association studies, to coronary artery disease in HIV-infected individuals 01.12.2009 Project funding (special)
134277 Swiss HIV Cohort Study (SHCS) 01.01.2011 Cohort Studies Large
124943 Pharmacocinétique de population, pharmacogénétique, et profils métaboliques de la thérapie anti-HIV 01.04.2009 Project funding (special)
177499 Swiss HIV Cohort Study (SHCS) 01.01.2018 Cohort Studies Large
144209 Dynamics of atherosclerosis progression in HIV-infected and HIV-uninfected persons - a longitudinal study using coronary computed tomography angiography 01.07.2013 Project funding (special)
148522 Swiss HIV Cohort Study (SHCS) 01.01.2014 Cohort Studies Large